Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 66 Publications

13 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MlO4R5l1d3SxeHnjJGF{e2G7 NVf2[HRyOTBibl2= MnfiO|IhcA>? MnzGSG1UVw>? M1HMcXBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> Ml2zNlQ6ODB6N{O=
HT-29 MlLaR5l1d3SxeHnjJGF{e2G7 M{jUSVExKG6P NIjufoY4OiCq NFzrWJFFVVOR MWDQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl? NV\zVoN5OjR7MEC4O|M>
HT-29 M3L4XGN6fG:2b4jpZ{BCe3OjeR?= M1LtcVExKG6P MXS3NkBp Mn;OSG1UVw>? MmfzVI91\W62aXH0[ZMhPS2obIXvdo92emGlaXytbY5lfWOnZDDjfZRwfG:6aXPpeJk> NVTl[phsOjR7MEC4O|M>
PC3 MnrpT4lv[XOnIFHzd4F6 MnPGNVAxKG6P NX65RYE4OSCq NIn0NINFVVOR NGT0VHRRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> Ml2yNlE6Pzh4OEO=
PC3 MnfOT4lv[XOnIFHzd4F6 M3qxSlExOCCwTR?= NGnEd2MyKGh? NEDIVHNFVVOR MV3Ec4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? M{no[FIyQTd6Nkiz
PC3 NFXUXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVixMlUh|ryP Mnv5NUBp NIH1[mdFVVOR NG\DdldKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= NWL0e3FJOjF7N{i2PFM>
HEK293 NF\JbndHfW6ldHnvckBCe3OjeR?= NYf1eIZIOTByIH7N MYS4JIg> M3TZO2ROW09? MVfJcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1? Mo\qNlE2Ozl|MEG=
BT-20 MY\LbY5ie2ViQYPzZZk> M2\URVIxKM7:TR?= NWnnXmtUTE2VTx?= NWX0OXQ5TG:nczDuc5QhcW6qaXLpeEBuXE:UQ{Kg[IVx\W6mZX70JJBCc1RiU{S3N{BxcG:|cHjvdplt[XSrb36= Moi0NlE{PTN3NUG=
U937 NHP0OYlCdnSrYnHjeIVzcWGuIFHzd4F6 NV7WO5RmPTBizszN MlHXOFghcA>? NF3QU3ZFVVOR MmewTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| Mk[0NlEyPDJzME[=
U937 NF33VItCdnSrYnHjeIVzcWGuIFHzd4F6 NF65XG02OCEQvF2= NWXhbYlzPDhiaB?= M4n5S2ROW09? MmPESI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? M1XuWVIyOTR{MUC2
U937 M365RmFvfGmkYXP0[ZJq[WxiQYPzZZk> MlXBOVAh|ryP MWK0PEBp MknGSG1UVw>? M1vldmRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ M4W0V|IyOTR{MUC2
MCF-7 NIi1WW5CfXSxcHjh[5khSXO|YYm= NHf4TGE{OCCwTR?= MXK0JIg> M2TNO2ROW09? M2HFN2lv\HWlZYOgZZV1d3CqYXf5 MYCyNFAzQDF|NB?=
U87MG NFzPNYJMcW6jc3WgRZN{[Xl? M1jDPVEh|ryP NFnQ[Y43KGh? MmOwSG1UVw>? MYfQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>? MofxNVk5PDh2MES=
U87MG Mkn5T4lv[XOnIFHzd4F6 MYSxJO69VQ>? NHmwc3A3KGh? NV3oXHN2TE2VTx?= Mn\XVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= NFLjcJYyQTh2OESwOC=>
U87MG MlXvT4lv[XOnIFHzd4F6 M3XYdVEh|ryP Mor6OkBp M13XWmROW09? MoS3SI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MWGxPVg1QDRyNB?=
U87MG M1rObGtqdmG|ZTDBd5NigQ>? Mli2NUDPxE1? MVG2JIg> MXnEUXNQ Mn;iSI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v M{PKZ|E6QDR6NEC0
COS7 cells expressing EGFP-HDQ74/rheb MmL0RZV1d3CqYXf5JGF{e2G7 NXG5b2RLOC5{IN88US=> NYT1SYttOjRiaB?= M1TPdmROW09? MnnkTY5lfWOnczDheZRweGijZ4m= MYGxPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 M{LuNGF2fG:yaHHnfUBCe3OjeR?= MlTYNE4zKM7:TR?= NHvPNFczPCCq NX[5ZYVPTE2VTx?= MWXJcoR2[2W|IHH1eI9xcGGpeR?= MVixPFM6OTl2OR?=
H4 M{TUNmZ2dmO2aX;uJGF{e2G7 NVXlXmx7OC5{IN88US=> Ml3xNlQhcA>? NYDzUlZtTE2VTx?= NEPYUXJKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{ NFG2RmMyQDB{NEW4OC=>
HeLa NWXRRnhCTnWwY4Tpc44hSXO|YYm= MnnsNVAxKG6P MoD0N|YhcA>? MnzHSG1UVw>? NUHBPZNoUW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? NH7abI0yPzV4M{O4OS=>
HeLa NHnMZYpHfW6ldHnvckBCe3OjeR?= NUfLOY9TOTByIH7N M1XqcFM3KGh? MWnEUXNQ MnTUTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v NF7vRXYyPzV4M{O4OS=>
HeLa MXzGeY5kfGmxbjDBd5NigQ>? MnGzNVAxKG6P NH\NPGU{PiCq M362OmROW09? Ml3GTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NYfDZ2RiOTd3NkOzPFU>
SYF MXvGeY5kfGmxbjDBd5NigQ>? M3;GPFExOCCwTR?= M3zB[VI1KGh? M4H3T2ROW09? MW\JcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= NW[4RWdtOTd3NkOzPFU>
SYF MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSxNFAhdk1? Mn\VNlQhcA>? M1vUOWROW09? NU\ZZVJGUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> NVHw[FZkOTd3NkOzPFU>
HEK293T NWW1SIFDSW62aY\pdoFtKEG|c3H5 NV\I[3lsOSCwTR?= NUnuU|lzPCCm NYT4VmZPTE2VTx?= NYTCOGk6UW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> M2PtZlE4PDh3NUCx
HEK293T NVXiZ5RISW62aY\pdoFtKEG|c3H5 Ml7mNUBvVQ>? NYm4cY5yPCCm M4fvbWROW09? M1TrV2lv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N NFrRUZUyPzR6NUWwNS=>
PBMC MkO3SpVv[3Srb36gRZN{[Xl? NIX5cpEyKG6P M17UcVE1KGR? NEDJcG1FVVOR M{K5NHJm\HWlZYOgR2NTPSCmZX7zbZR6 MWqxO|Q5PTVyMR?=
PBMC MXrGeY5kfGmxbjDBd5NigQ>? MoLnNUBvVQ>? Mn\hNVQh\A>? NGHuNGpFVVOR MX;Ec4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> NXPNXXE{OTd2OEW1NFE>
HEK293 cells M{D0bGtqdmG|ZTDBd5NigQ>? NEfYUWM2OCCwTR?= NXXqOHB6PDVibXnu NGfac2tFVVOR MXjJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O NYPFVGlqOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MVfGeY5kfGmxbjDBd5NigQ>? MVGxNFAhdk1? Mn24OEBp NX7p[3BuTE2VTx?= MnnUTY5lfWOnczDseYNq\mW{YYPlJJBzd3SnaX6geJJidnNvc4DsbYNqdmdiaX6gSJJwe2:yaHnsZUBu\Wyjbn;nZZN1\XJiU{KgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCQLXz1Z{BidmRiQz3seYM> Mm\iNVcyOjh{NkK=
Human mixed lymphocyte MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP5ZmNmPSCwTR?= M4Dt[2ROW09? MY\JR|UxRTFwNjDuUU4> Mk\QNVYyQDV6NkW=
Lewis rat lymph node cells MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7uVFNvPSEQvF2= MW\EUXNQ MUXJR|UxRTJwNjFOwG0> NIPIcWcyPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice M1H2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqxNEBvVQ>? NX7SdnlQPzJiaB?= M4jIcmROW09? NH\vXm1KdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N NUDyXHpUOTByMkG5OFg>
MRK-nu-1 MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoryTWM2OD1yLki0OUBxVQ>? MVnTRW5ITVJ?
OCUB-M MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPoeWNbUUN3ME21MlI1KHCP NELS[WVUSU6JRWK=
SF539 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzGVVRKSzVyPUGxMlYheE1? NIK4VZFUSU6JRWK=
ES4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf2RY5zUUN3ME2yNU42KHCP NWLSOVRNW0GQR1XS
RL95-2 M1PPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO5c3FKSzVyPUGwO{BxVQ>? MmmxV2FPT0WU
LC-2-ad M4rFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HWW2lEPTB;NEKzJJBO NV\UVFV{W0GQR1XS
Daudi MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTR|NDDwUS=> M2XtPHNCVkeHUh?=
NTERA-S-cl-D1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTR2MzDwUS=> Ml7NV2FPT0WU
OS-RC-2 NHnpeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLWTWM2OD14NUKgdG0> M3fMe3NCVkeHUh?=
VA-ES-BJ Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTd{MzDwUS=> Mn7BV2FPT0WU
GR-ST MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\XVFNKSzVyPUi0OkBxVQ>? NFrDXI1USU6JRWK=
SW872 M2rkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjQ[I5GUUN3ME24OFYheE1? NGXaNJdUSU6JRWK=
NOS-1 NYOzUnpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjlTWM2OD16N{GgdG0> NH;sbFlUSU6JRWK=
MC116 Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr0epZKSzVyPUm4OUBxVQ>? NFPzPGFUSU6JRWK=
NCI-H1355 M3LVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGzRWtKSzVyPUGuNFEhdk1? NXTYO5ZOW0GQR1XS
RPMI-8226 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDnTWM2OD1zLkG5JI5O MoD3V2FPT0WU
TE-15 M2iySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\iZ2hRUUN3ME2xMlM3KG6P MYDTRW5ITVJ?
Ramos-2G6-4C10 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwNE[gcm0> MY\TRW5ITVJ?
KU812 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XDfGlEPTB;Mj6wNUBvVQ>? NVvVVphWW0GQR1XS
EW-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3kdo9IUUN3ME2yMlE4KG6P M33pPXNCVkeHUh?=
KS-1 NVi4VFFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTY[W1KSzVyPUKuOFUhdk1? Mn7lV2FPT0WU
SK-LMS-1 NYDEXW1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJwNEmgcm0> NUSzXmg5W0GQR1XS
TGBC1TKB NX;yUmhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;pR2lEPTB;Mj62PUBvVQ>? NUPmR4pPW0GQR1XS
TE-6 MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXYXG5sUUN3ME2yMlc4KG6P NFP5NlNUSU6JRWK=
ETK-1 NITpV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfrV3F4UUN3ME2yMlgzKG6P MY\TRW5ITVJ?
BE-13 NXPZfoNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJwOUmgcm0> MU\TRW5ITVJ?
A3-KAW NWj6UHM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13ZS2lEPTB;Mj65PUBvVQ>? MnrBV2FPT0WU
TE-10 NGryU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXpUnA6UUN3ME2zMlMhdk1? NIHJbGtUSU6JRWK=
DOHH-2 M3PTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXMbnpKSzVyPUOuN|Uhdk1? MnTtV2FPT0WU
ES6 NIPEO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LrRWlEPTB;Mz60N{BvVQ>? NIDv[XNUSU6JRWK=
OPM-2 NUPYTlJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfITWM2OD12LkG1JI5O NVrmZVFKW0GQR1XS
SH-4 NYTo[|ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLITWM2OD12LkO0JI5O M130[3NCVkeHUh?=
NB13 NWnCbYR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPZPGtsUUN3ME20MlM3KG6P MXjTRW5ITVJ?
HUTU-80 NUXDZppkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTRwNEKgcm0> NUnUN4ZlW0GQR1XS
CCRF-CEM M{H6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLWeGRkUUN3ME20Mlk1KG6P M2Pve3NCVkeHUh?=
TGBC24TKB NY\GTlRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rIS2lEPTB;NT61NUBvVQ>? NEXXbWRUSU6JRWK=
697 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPsXJpZUUN3ME22MlI5KG6P NVTLbGRMW0GQR1XS
J-RT3-T3-5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjNTWM2OD14LkS2JI5O NWPHT5M5W0GQR1XS
KALS-1 NWf1SXlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3BbnBKSzVyPU[uOVYhdk1? MXPTRW5ITVJ?
no-10 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTdwMkmgcm0> NHjWOnlUSU6JRWK=
SK-NEP-1 NXTneHhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDrboRKSzVyPUiuO|khdk1? NYO2T|RtW0GQR1XS
L-540 NUfTOHRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn0WJJvUUN3ME2xNE41OiCwTR?= NEixNmJUSU6JRWK=
JiyoyeP-2003 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXtOJF2UUN3ME2xNE46PCCwTR?= Ml\4V2FPT0WU
HH M{S3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3JNGFKSzVyPUGxMlM6KG6P NFi2fFRUSU6JRWK=
SR NEXPe2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT0TWM2OD1zMT60OUBvVQ>? NHPBfYVUSU6JRWK=
QIMR-WIL NVfLUYh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi2TWM2OD1zMT64OUBvVQ>? NEfZU49USU6JRWK=
A4-Fuk NIDydoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2SxeWlEPTB;MUOuNVIhdk1? NFfoXpNUSU6JRWK=
CESS NX76UplRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[2TWM2OD1zMz6xN{BvVQ>? M33PdnNCVkeHUh?=
KE-37 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXBXnlKSzVyPUG2MlA4KG6P MV3TRW5ITVJ?
SK-UT-1 M4XkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfPdWJKSzVyPUG2MlgyKG6P MnL5V2FPT0WU
SIG-M5 M3PZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHziOItKSzVyPUG3MlI2KG6P MYrTRW5ITVJ?
HT MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f5PWlEPTB;MUeuOkBvVQ>? NHPrcmFUSU6JRWK=
DEL NYnYWnA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXlTWM2OD1zNz65PUBvVQ>? NF7xW3hUSU6JRWK=
SK-PN-DW MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml30TWM2OD1{MD6yN{BvVQ>? MknqV2FPT0WU
RPMI-8402 MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DQdmlEPTB;MkGuO|chdk1? NHPkSnZUSU6JRWK=
RPMI-6666 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXGc|ZNUUN3ME2yOE41OiCwTR?= NGf4cGFUSU6JRWK=
NCI-H720 NEX5eHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTFcHdKSzVyPUK1MlQyKG6P Mm\QV2FPT0WU
EW-16 MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3PeXFPUUN3ME2yOk45PyCwTR?= MnHuV2FPT0WU
BL-70 MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJ6LkO4JI5O MWLTRW5ITVJ?
SF126 M4L4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTNyLkO4JI5O MknrV2FPT0WU
BC-1 M1\uUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTnRpl2UUN3ME2zNU4zPiCwTR?= NHjUSVFUSU6JRWK=
MHH-PREB-1 M1PoUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\mOm9KSzVyPUOyMlQ1KG6P MVHTRW5ITVJ?
A101D MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrrTlhKSzVyPUOyMlYzKG6P M{P4PHNCVkeHUh?=
NMC-G1 M3Hvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljJTWM2OD1|Mz62O{BvVQ>? M2iwPXNCVkeHUh?=
LB1047-RCC M{Xad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS4XVJKSzVyPUO0MlY6KG6P NXTTSIxZW0GQR1XS
EM-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7kTWM2OD1|OD61N{BvVQ>? NVmyZ5NUW0GQR1XS
COLO-684 M1O0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfSTWM2OD1|OT64JI5O MUDTRW5ITVJ?
Becker NVz2cVVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTRzLkC1JI5O NIPpTndUSU6JRWK=
BL-41 NIjZUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfkTWM2OD12Mz62OkBvVQ>? M1S2WnNCVkeHUh?=
MDA-MB-134-VI MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml21TWM2OD12ND6wNkBvVQ>? M1vEZnNCVkeHUh?=
L-363 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnYTWM2OD12ND63N{BvVQ>? M3PETnNCVkeHUh?=
ECC4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13lRWlEPTB;NESuO|ghdk1? NWKyWFlbW0GQR1XS
A388 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml30TWM2OD12ND64NkBvVQ>? MknCV2FPT0WU
HEL NYT6UIU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnpN3JtUUN3ME20PU44QSCwTR?= NUPsS4ZLW0GQR1XS
RKO MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTVyLkK5JI5O MmXHV2FPT0WU
KINGS-1 M{LSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvxXY9xUUN3ME21NU42PSCwTR?= NEHENJVUSU6JRWK=
EB-3 MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHZbWpKSzVyPUWyMlY4KG6P M2LCb3NCVkeHUh?=
ARH-77 NWjLO4U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nwcWlEPTB;NUKuPEBvVQ>? NEPpfFVUSU6JRWK=
GCIY NX[1S3l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTV|LkS2JI5O M2DxUHNCVkeHUh?=
NCI-H1304 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3BTWM2OD13Nz6yNkBvVQ>? NXTMTJc3W0GQR1XS
KARPAS-299 NHvSS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTZzLkiyJI5O M33TbHNCVkeHUh?=
IA-LM NVrXW5pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\vTWM2OD14OD6xN{BvVQ>? M2O0Z3NCVkeHUh?=
GI-1 NWPyT|k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4KzSWlEPTB;N{CuN|khdk1? M3\3VHNCVkeHUh?=
TE-11 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HQcGlEPTB;N{euNVchdk1? Mom2V2FPT0WU
LS-411N MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTd5LkW3JI5O NITWeXJUSU6JRWK=
no-11 M33JTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm5SJR6UUN3ME24N{4zPCCwTR?= MnvZV2FPT0WU
MV-4-11 NIjibHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HwPGlEPTB;OEOuO|Mhdk1? MUTTRW5ITVJ?
BV-173 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PhSmlEPTB;OEOuPVchdk1? NGXIcFVUSU6JRWK=
CMK NWjuWpNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LWbGlEPTB;OESuNVYhdk1? M1P3N3NCVkeHUh?=
LC4-1 NU\HR5lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPyT4pZUUN3ME24Ok44OiCwTR?= MUTTRW5ITVJ?
COR-L279 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zITmlEPTB;OEeuNlUhdk1? MkfWV2FPT0WU
NCI-H209 NXrTUHRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NISyfXFKSzVyPUi3MlQyKG6P MofoV2FPT0WU
Raji NYjhbHlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL2cXc2UUN3ME24PU44OiCwTR?= MWHTRW5ITVJ?
LB996-RCC NGewXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXNSYVmUUN3ME25N{41OyCwTR?= Ml;MV2FPT0WU
NCI-H526 MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnyUpNUUUN3ME25N{42QSCwTR?= NInvSXJUSU6JRWK=
KGN NVLwVm5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7wTWM2OD17Nj6yPUBvVQ>? NEH6NXdUSU6JRWK=
MOLT-4 NH:2Z3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7MdpJjUUN3ME25Ok44QSCwTR?= Ml7UV2FPT0WU
PF-382 NIflcFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnER4ZKSzVyPUm2Mlc6KG6P MojHV2FPT0WU
BC-3 M2Cxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3yTHRKSzVyPUm5MlE5KG6P NWfNT2hNW0GQR1XS
KARPAS-422 NGPkSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTwZXZKSzVyPUGwNk4xQSCwTR?= M4\SOnNCVkeHUh?=
SBC-1 NGrhe2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnwblNKSzVyPUGwO{44PSCwTR?= MkDiV2FPT0WU
LC-1F MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rVRmlEPTB;MUC4MlA2KG6P MVnTRW5ITVJ?
GB-1 MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH3fnFqUUN3ME2xNFkvODJibl2= NYHFSHVEW0GQR1XS
SNB75 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTFzOT62PUBvVQ>? NWSxOZA5W0GQR1XS
BB65-RCC M1;zSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFzOT65N{BvVQ>? MlG1V2FPT0WU
NCI-N87 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPYc3NKSzVyPUGyNU46QCCwTR?= M1fxVXNCVkeHUh?=
IST-MEL1 NGXNfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLKTWM2OD1zMkKuN|ghdk1? NHvzeFRUSU6JRWK=
HOP-62 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF{Nj64PUBvVQ>? NFPoTlFUSU6JRWK=
ACN M4Cxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D2OWlEPTB;MUS2Mlc2KG6P MojFV2FPT0WU
DMS-114 NG\S[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TxZ2lEPTB;MUWwMlY4KG6P M13rSnNCVkeHUh?=
MLMA NGrUNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1y0Z2lEPTB;MUW5Mlg5KG6P MXXTRW5ITVJ?
HT-144 NGi4dJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HaUmlEPTB;MU[1MlQ{KG6P NUe5[HlyW0GQR1XS
C2BBe1 MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDkN5hZUUN3ME2xOlcvPzZibl2= MYTTRW5ITVJ?
L-428 NILafY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHyNWNwUUN3ME2xO|cvPyCwTR?= MlH6V2FPT0WU
DU-4475 NVOwXJJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITKSXVKSzVyPUG4O{43QCCwTR?= M4PrTnNCVkeHUh?=
CP67-MEL MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF7OT6zPEBvVQ>? M3vz[3NCVkeHUh?=
MEG-01 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXq[3V1UUN3ME2yNFEvQTZibl2= M2rQUHNCVkeHUh?=
IST-SL2 NE\tc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJyOD62N{BvVQ>? M4K0UXNCVkeHUh?=
ES8 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ{NT65OEBvVQ>? MoP1V2FPT0WU
COLO-800 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTUTWM2OD1{M{WuNlghdk1? NYCxS3p5W0GQR1XS
MFH-ino Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHTTWM2OD1{M{WuPFQhdk1? Ml36V2FPT0WU
OVCAR-4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfPToVKSzVyPUKzO{4zPCCwTR?= MmjWV2FPT0WU
PSN1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJ2Mj63NUBvVQ>? NHT5fYNUSU6JRWK=
EW-12 NU\jb5FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjzXGFkUUN3ME2yOFMvOSCwTR?= MoDOV2FPT0WU
HCC1599 NFXQcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PUUGlEPTB;Mk[xMlQ4KG6P M1rTTnNCVkeHUh?=
SJSA-1 M1\lUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v1[2lEPTB;MkexMlQ3KG6P M3O5b3NCVkeHUh?=
ST486 NH\YbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPqUG9KSzVyPUK5Ok4yPCCwTR?= MlP0V2FPT0WU
NOMO-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICwdlVKSzVyPUOwNE4zOSCwTR?= NYTJd3RFW0GQR1XS
MN-60 NXe5dJdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\zeIlXUUN3ME2zNFUvOzJibl2= M1P2cHNCVkeHUh?=
HCC1187 NUO0RW13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3iTWM2OD1|MEeuNlUhdk1? MmHKV2FPT0WU
SW982 M{\IOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP4PWZKSzVyPUOxOE44PSCwTR?= NGTxdG5USU6JRWK=
LB647-SCLC NX;VXGE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTN{OD63NUBvVQ>? NF7OTXBUSU6JRWK=
HC-1 NYKyeYU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTN|NT61JI5O NGLEenpUSU6JRWK=
EHEB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\mOmlEPTB;M{O3MlUzKG6P Mlr6V2FPT0WU
TUR MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLrTWM2OD1|NkOuPVUhdk1? NEPZOZZUSU6JRWK=
LU-139 Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnflTWM2OD1|N{iuNFIhdk1? NXPvNoJyW0GQR1XS
NB1 NU[3OGQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTN6ND60OUBvVQ>? Mo\3V2FPT0WU
BB30-HNC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi2cJVKSzVyPUO4PE4{OiCwTR?= MXHTRW5ITVJ?
HAL-01 M{G0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LHS2lEPTB;M{i5MlI3KG6P MYfTRW5ITVJ?
K5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTRzMT6zO{BvVQ>? NYjF[VhsW0GQR1XS
MZ2-MEL MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTRzMz62OEBvVQ>? NH;tNoRUSU6JRWK=
RXF393 MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\TTWM2OD12MU[uOFUhdk1? Mm\HV2FPT0WU
NCI-H1648 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7RfIpKSzVyPUSxO{42OyCwTR?= MmXmV2FPT0WU
TE-12 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXvTWM2OD12M{SuNlYhdk1? MlPBV2FPT0WU
EoL-1- MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPYTWM2OD12M{euPVghdk1? MWDTRW5ITVJ?
JAR MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonHTWM2OD12M{iuOlIhdk1? M1vyZnNCVkeHUh?=
DSH1 MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTR3OD65NUBvVQ>? Mm\DV2FPT0WU
NCI-H187 M2nJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;Bcm5KSzVyPUS2Nk45OSCwTR?= MkC0V2FPT0WU
HCE-4 NEPVb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTnTWM2OD12N{euOlYhdk1? M1S2PXNCVkeHUh?=
8-MG-BA MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTV6MT61NkBvVQ>? MkXRV2FPT0WU
KLE NXT5ZWxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIflbFNKSzVyPUW4OU4zKG6P MUDTRW5ITVJ?
KNS-42 NEm0SYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXpPGxWUUN3ME21PFYvQDFibl2= Mki4V2FPT0WU
MSTO-211H M{jMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTZyOT63OEBvVQ>? NVXRTnkyW0GQR1XS
GDM-1 NWHBZ2lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDoXlM2UUN3ME22NVQvODlibl2= NVr2TVdTW0GQR1XS
TE-1 MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;KN2lEPTB;NkS2MlEzKG6P Moe2V2FPT0WU
BT-474 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkKyTWM2OD14NEeuNFYhdk1? NXT2XmNRW0GQR1XS
KARPAS-45 M2LiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTZ2Nz62JI5O NXnLc4M{W0GQR1XS
MOLT-16 M2nET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTZ2Nz65N{BvVQ>? NUHBZWdXW0GQR1XS
KURAMOCHI M1HEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PVdGlEPTB;NkW3MlUyKG6P MU\TRW5ITVJ?
K-562 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTZ4OT61NUBvVQ>? MVrTRW5ITVJ?
EKVX MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL3N2R[UUN3ME22O|IvPzFibl2= M2jWOHNCVkeHUh?=
GAK MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe2e4lNUUN3ME22O|UvOyCwTR?= MUPTRW5ITVJ?
NCI-SNU-5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTZ7MD6wNUBvVQ>? MXjTRW5ITVJ?
NCI-H2126 M3;oWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOxOGFKSzVyPUeyOk45PyCwTR?= MYnTRW5ITVJ?
CTV-1 NWC0N25TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nwNmlEPTB;N{S0Mlkhdk1? MknRV2FPT0WU
SW962 M3G5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzzXHNKSzVyPUe0PE41PCCwTR?= NEjIPJRUSU6JRWK=
MONO-MAC-6 M1zXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Pxb2lEPTB;N{W2Mlk{KG6P M3f1SHNCVkeHUh?=
NCI-H748 NGLtTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7WcJdrUUN3ME23OVgvQTlibl2= MmexV2FPT0WU
NCI-H524 MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjUUIRKSzVyPUe4NE44OyCwTR?= MYDTRW5ITVJ?
LS-123 NH;r[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHOR2xFUUN3ME23PVUvPjlibl2= MofBV2FPT0WU
NB7 MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\STWM2OD16MUSuNVQhdk1? MU\TRW5ITVJ?
LS-1034 NFGzfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnraTWM2OD16MkiuPVghdk1? NGDI[GJUSU6JRWK=
TE-5 M4qzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[zTWM2OD16OEOuOVYhdk1? NFTYfGRUSU6JRWK=
A704 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vSV2lEPTB;OEm5MlE2KG6P MXjTRW5ITVJ?
TK10 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG4XpE{UUN3ME25NVYvODNibl2= NWTHeZRTW0GQR1XS
NCI-H345 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXviOZN3UUN3ME25OFMvOjJibl2= NYrEfll2W0GQR1XS
CGTH-W-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHUTWM2OD17NEiuNVMhdk1? M2LpW3NCVkeHUh?=
NCI-H510A MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu1[4VKSzVyPUm4OU4yOiCwTR?= NV75fVhCW0GQR1XS
NCI-H1963 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFwMEOyPVIh|ryP NVv1[JVVW0GQR1XS
SCC-3 NGDk[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHkPGpKSzVyPUGuNFM1OTRizszN MWrTRW5ITVJ?
EW-11 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\CSWx1UUN3ME2xMlA5PzR|IN88US=> MUXTRW5ITVJ?
CPC-N MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHnTWM2OD1zLkC4PEDPxE1? MYPTRW5ITVJ?
NCI-H1417 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H2S2lEPTB;MT6xNlI3KM7:TR?= NXLPOYtGW0GQR1XS
DG-75 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn74TWM2OD1zLkG2Nlg2KM7:TR?= NVfhRYluW0GQR1XS
HD-MY-Z NIT6Ro1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTSTWM2OD1zLkG2OFE3KM7:TR?= M2fQU3NCVkeHUh?=
ATN-1 NVzPSHczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFwMk[yNFkh|ryP M2j5OXNCVkeHUh?=
KM-H2 NYexSHRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7jRoJKSzVyPUGuNlY1ODhizszN NXzvRVlwW0GQR1XS
NCI-H2081 NYTIVW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwMk[2N|ch|ryP M{HjbnNCVkeHUh?=
HL-60 NXvS[W5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nkO2lEPTB;MT6yOlk2QSEQvF2= MUDTRW5ITVJ?
DB MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvETWM2OD1zLkK3NlQzKM7:TR?= MXLTRW5ITVJ?
NCI-H1522 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XZXWlEPTB;MT6yPFg5PyEQvF2= Ml3TV2FPT0WU
AM-38 M1uzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnwTWM2OD1zLkOwO|Ih|ryP M3:3e3NCVkeHUh?=
NCI-H446 M{XCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDaTWM2OD1zLkOyNVIyKM7:TR?= MmjqV2FPT0WU
SU-DHL-1 NYLi[YtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PzbWlEPTB;MT6zNlgxOSEQvF2= M3nh[XNCVkeHUh?=
NH-12 NYjKVWsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\2d49pUUN3ME2xMlM3Ozd2IN88US=> M3K3dHNCVkeHUh?=
DMS-79 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLvTWM2OD1zLkO2PFY3KM7:TR?= Mm\UV2FPT0WU
NCI-H716 MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LGfWlEPTB;MT6zPFk5PiEQvF2= NFL1SmlUSU6JRWK=
ML-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XxfGlEPTB;MT60NVUzQSEQvF2= NFTrbm1USU6JRWK=
NB10 NXOwfHRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwNE[2N|Ih|ryP NX7Fe29wW0GQR1XS
ONS-76 NVTUd2NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwNUO1Olkh|ryP NWTxPWhOW0GQR1XS
LOUCY M4\Ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLDTWM2OD1zLkW0OlU4KM7:TR?= MUHTRW5ITVJ?
SCLC-21H NYSzRXNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjnN|ZKSzVyPUGuOVg2QDJizszN NHrEPGtUSU6JRWK=
TGW NGD5VW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwNkO5O|Uh|ryP M3HmcnNCVkeHUh?=
LXF-289 M13IPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LDWWlEPTB;MT63N|I3QCEQvF2= Mm\qV2FPT0WU
BB49-HNC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwN{O1PFYh|ryP Mo\FV2FPT0WU
NCI-H747 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XFTmlEPTB;MT63OVM1PiEQvF2= MVrTRW5ITVJ?
LU-165 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW3TWM2OD1zLki0PVg3KM7:TR?= NEHwR25USU6JRWK=
OMC-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHlTWM2OD1zLkm1NFY3KM7:TR?= MVzTRW5ITVJ?
RCC10RGB MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFwOUW4NVch|ryP MmP6V2FPT0WU
SW684 NEHtc|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf4RlU1UUN3ME2xMlk3ODl7IN88US=> NV:zR5pyW0GQR1XS
TE-8 NILHOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCyTWM2OD1{LkC1OVU6KM7:TR?= MnTGV2FPT0WU
SK-N-DZ M{naPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjobFZVUUN3ME2yMlE{Ojd2IN88US=> NVu0e3JTW0GQR1XS
EVSA-T NU\PcWhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrkUI1KSzVyPUKuNVc{OTVizszN MXTTRW5ITVJ?
KASUMI-1 NVXSelM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XpSGlEPTB;Mj6xPFgyPSEQvF2= NV\TSnh7W0GQR1XS
NKM-1 M2O5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jwO2lEPTB;Mj6yOVQ4OiEQvF2= NXzrOYQ6W0GQR1XS
CAL-148 MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf5UIdKSzVyPUKuN|M3OTRizszN M2XnTnNCVkeHUh?=
NCI-H64 Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnywTWM2OD1{LkO0NlMzKM7:TR?= MXfTRW5ITVJ?
KNS-81-FD NEnYSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\JTG0{UUN3ME2yMlM3PjJizszN NWDhWm9pW0GQR1XS
KM12 NFPTcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJwNEC4N|kh|ryP NYfydoxuW0GQR1XS
SW954 M17pPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJwNEe3O|kh|ryP MWnTRW5ITVJ?
NCI-H1395 NWW2OWFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwNUK2OFUh|ryP NEfjUWNUSU6JRWK=
DJM-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu5TWM2OD1{Lk[wOlMh|ryP MlTWV2FPT0WU
COLO-668 NIi1cZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLDTWM2OD1{LkiyOlk2KM7:TR?= MXnTRW5ITVJ?
NCI-H1436 MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULISGlWUUN3ME2yMlg2PjF3IN88US=> MniwV2FPT0WU
LB2241-RCC NITKfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j6eGlEPTB;Mj64Olg{QSEQvF2= NYX6XHJQW0GQR1XS
GT3TKB Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rCZmlEPTB;Mj64PVA2PSEQvF2= MXHTRW5ITVJ?
COLO-824 M{LvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P4emlEPTB;Mj64PVc3QCEQvF2= M1OzT3NCVkeHUh?=
ES1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrOSnZUUUN3ME2yMlg6QDd7IN88US=> MV7TRW5ITVJ?
LB771-HNC NH7VeWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH6e45yUUN3ME2yMlkxQTR4IN88US=> M{HBc3NCVkeHUh?=
GI-ME-N Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13BbGlEPTB;Mz6wNFkxPCEQvF2= Mn2xV2FPT0WU
NALM-6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTySZYxUUN3ME2zMlAxQTN|IN88US=> MnXTV2FPT0WU
LU-134-A NWXnV5Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNwMEW0NlUh|ryP NVX1d|hCW0GQR1XS
DMS-153 NWrkUXNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u1[2lEPTB;Mz6wOVgzPCEQvF2= MoixV2FPT0WU
MZ1-PC NH7jempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX5TWM2OD1|LkC5NFc5KM7:TR?= MYnTRW5ITVJ?
NCI-H1155 NXfHR4NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HPbmlEPTB;Mz6xNVYyKM7:TR?= MXXTRW5ITVJ?
CAS-1 NWDHXVU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTNwMUO3NFch|ryP Mn70V2FPT0WU
D-502MG NFfUW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTNwMUSzPUDPxE1? NUjqSmY5W0GQR1XS
NCI-H2141 NIHPO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLhV2tKSzVyPUOuNVc1PTJizszN MkTSV2FPT0WU
NB6 M2i1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTNwMUiyOVkh|ryP MojhV2FPT0WU
NCCIT NVv0S3JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfUcZJKSzVyPUOuNlE5ODlizszN MVrTRW5ITVJ?
NB69 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XBd2lEPTB;Mz6zNVg6OSEQvF2= Mn7vV2FPT0WU
JVM-2 NHT4W5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNwM{[0N|Mh|ryP NVfnbFZ{W0GQR1XS
K052 MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTNwM{e5Olgh|ryP NIHZV4FUSU6JRWK=
HCC2157 NFXTV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LtWGlEPTB;Mz61N|IzQCEQvF2= NXjUellOW0GQR1XS
KMOE-2 NYXlfnB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTNwNUSyOFIh|ryP NHTNeWFUSU6JRWK=
SF268 NH\6dWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTNwN{G1OVQh|ryP NWnrRYpJW0GQR1XS
CHP-126 M4PjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfVT4JKSzVyPUOuO|Y1PThizszN M37qWHNCVkeHUh?=
CP66-MEL MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO2UWhwUUN3ME2zMlc6ODl2IN88US=> NFjYc2RUSU6JRWK=
NCI-H69 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrsTWM2OD12LkCxPVM3KM7:TR?= M{f3dnNCVkeHUh?=
A253 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIflc2xKSzVyPUSuNFIyODFizszN NIT5XVJUSU6JRWK=
NB14 M{nPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXyTWM2OD12LkGwOFc6KM7:TR?= MmrZV2FPT0WU
NCI-H1694 M4S5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PicmlEPTB;ND6xN|EyOiEQvF2= M3nvS3NCVkeHUh?=
NCI-H2196 NGHpPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrOcmV{UUN3ME20MlE4OTZ7IN88US=> MkLIV2FPT0WU
TE-9 NYLoeZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3DTWM2OD12LkG3OVgzKM7:TR?= NGfTW2ZUSU6JRWK=
D-283MED NWW0WVdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTRwMUi4OEDPxE1? MmnUV2FPT0WU
OCI-AML2 M4ix[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVToU3FkUUN3ME20MlE6PDh7IN88US=> M4LDOnNCVkeHUh?=
D-263MG M3nmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\JOmlkUUN3ME20MlIzQTZzIN88US=> MlTEV2FPT0WU
MPP-89 MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnlTWM2OD12LkK3N|A1KM7:TR?= MXPTRW5ITVJ?
LAMA-84 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\Fd29KSzVyPUSuN|A1OjFizszN MWjTRW5ITVJ?
LB373-MEL-D NWDIeY1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTRwM{[3PFkh|ryP NGGyOYJUSU6JRWK=
UACC-257 MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPETZZKSzVyPUSuN|k2OzRizszN NXntPXNyW0GQR1XS
MC-CAR MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\oenhKSzVyPUSuOFM6QSEQvF2= Ml;iV2FPT0WU
COLO-320-HSR M{TkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuxTZBKSzVyPUSuOFQ1OjdizszN MmT4V2FPT0WU
P30-OHK MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqzTWM2OD12Lk[2OVgyKM7:TR?= NGDGXFBUSU6JRWK=
UACC-812 NFTiUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjvTWM2OD12Lk[5NVYyKM7:TR?= NYfvfIxqW0GQR1XS
CTB-1 NIPvU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;BfGlEPTB;ND63NVU2PSEQvF2= M4LkTnNCVkeHUh?=
ALL-PO NXrp[XZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTRwOESwO|ch|ryP NETXcnVUSU6JRWK=
SK-MEL-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTRwOE[5OVUh|ryP MnX6V2FPT0WU
TC-YIK M3PDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjsTWM2OD12Lkm3PVQzKM7:TR?= NFnTUolUSU6JRWK=
NCI-H1882 Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzzTWhSUUN3ME21MlAzODBzIN88US=> MXvTRW5ITVJ?
MHH-CALL-2 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTVwMEWwOFIh|ryP MkC3V2FPT0WU
U-87-MG NHfNSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzzS4o2UUN3ME21MlA6PDZ4IN88US=> NFzURZdUSU6JRWK=
NCI-H1092 NFe2eVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHH4bIFKSzVyPUWuNlY2PTVizszN MonaV2FPT0WU
TE-441-T MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHKdGV5UUN3ME21MlI4QDJizszN NX:1TJM6W0GQR1XS
SK-MEL-1 M2HOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC5TWM2OD13LkK5NFQ1KM7:TR?= M{LxUnNCVkeHUh?=
EW-22 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTveYdPUUN3ME21MlI6PDZ4IN88US=> NIX4UGdUSU6JRWK=
MZ7-mel NGTjS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrNTWM2OD13LkSwOlkyKM7:TR?= M3TZRnNCVkeHUh?=
LP-1 NGriNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrFSYNtUUN3ME21MlQyOjlzIN88US=> Mm\QV2FPT0WU
NCI-SNU-16 MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfiXVVTUUN3ME21MlY1ODd2IN88US=> Ml\yV2FPT0WU
LU-65 NEDHV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLYTWM2OD13Lke2N|c{KM7:TR?= MVvTRW5ITVJ?
CW-2 M2\NTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nwO2lEPTB;NT64OVk2QSEQvF2= M37TOXNCVkeHUh?=
WSU-NHL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLtNVVmUUN3ME21Mlk2OTd2IN88US=> NF3KW5VUSU6JRWK=
IST-MES1 NEDneo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDPOpBKSzVyPUWuPVU1PDNizszN NHfmOG1USU6JRWK=
U-266 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnEOGZCUUN3ME21Mlk5OjB{IN88US=> Mlz2V2FPT0WU
TALL-1 NIrUU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS2TWM2OD14LkG0Olg5KM7:TR?= M4LmUHNCVkeHUh?=
Calu-6 NEjNUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTZwMUWzNVYh|ryP Mm\pV2FPT0WU
MMAC-SF M17TU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LaeGlEPTB;Nj6xPFU2PiEQvF2= NGLPRplUSU6JRWK=
NCI-H82 MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTZwMkC0PFkh|ryP NEXsTHlUSU6JRWK=
RS4-11 NGLyRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvyTWM2OD14LkK1PFk4KM7:TR?= NVTGd|BtW0GQR1XS
SNU-C2B MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHxNnJKSzVyPU[uOFA6PjlizszN MXrTRW5ITVJ?
BOKU MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTZwNEe1PVch|ryP Mm\pV2FPT0WU
C8166 NYLBOJpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\3dmlEPTB;Nj61OVkyOiEQvF2= NWj1fWt3W0GQR1XS
D-247MG NIT3b25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j4eGlEPTB;Nz6wOFM1PyEQvF2= NF:xS5pUSU6JRWK=
EW-18 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPob2VoUUN3ME23MlA4Ojl{IN88US=> NHT4NpJUSU6JRWK=
KG-1 NXy3NWxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TjeGlEPTB;Nz62Nlc{QCEQvF2= NWfVXJNWW0GQR1XS
REH M{fGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTdwNkixNFkh|ryP NUfBcY9wW0GQR1XS
U-698-M M4C2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvKcJVKSzVyPUeuPFQ{OTVizszN NWDaW|FWW0GQR1XS
KP-N-RT-BM-1 NGC4[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fTXWlEPTB;Nz65N|AzQSEQvF2= M161fXNCVkeHUh?=
MS-1 NIjtWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHrdHBKSzVyPUeuPVYxPDFizszN NGrX[VFUSU6JRWK=
SNU-C1 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfWbWdrUUN3ME23Mlk5OTl{IN88US=> NHrWXFJUSU6JRWK=
SK-MM-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGftSpZKSzVyPUiuNlYxPjVizszN MXrTRW5ITVJ?
LAN-6 NXnWeldyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuwVYdUUUN3ME24MlMxODBzIN88US=> MWXTRW5ITVJ?
NEC8 M4jNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrueGsxUUN3ME24MlMxPjlzIN88US=> MXvTRW5ITVJ?
NCI-H1770 NIi4TnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXmxdHZZUUN3ME24MlM5ODB{IN88US=> NHPmPWdUSU6JRWK=
D-336MG Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRThwNECxNVYh|ryP NVT5TnFjW0GQR1XS
COLO-829 MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3rZVBKSzVyPUiuOFg5PzlizszN Mm\hV2FPT0WU
LS-513 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDRR2tKSzVyPUiuOVk2QTlizszN M17nRnNCVkeHUh?=
YT MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXsTWM2OD16Lk[yOFI4KM7:TR?= NVTWXmZYW0GQR1XS
EW-24 NYO5bmxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LqdGlEPTB;OD63OlU1KM7:TR?= NH3sRohUSU6JRWK=
IST-SL1 Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfEU5ZKSzVyPUiuPFY2PDNizszN MVzTRW5ITVJ?
CA46 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz1V2RKSzVyPUiuPVUxQThizszN NXK5clk4W0GQR1XS
NCI-H1838 NYm1XZJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHvTWM2OD16Lkm4OlAzKM7:TR?= Mkn2V2FPT0WU
NCI-H719 MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P4cmlEPTB;OT6yOVI4QSEQvF2= MonlV2FPT0WU
HCE-T MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKwSYRKSzVyPUmuN|A5PTFizszN MX;TRW5ITVJ?
A498 NIPqRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fqfmlEPTB;OT6zOlEzPCEQvF2= NFXJSZdUSU6JRWK=
LB831-BLC MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjtRY1KSzVyPUmuO|Y2OjFizszN M2m0[XNCVkeHUh?=
SKM-1 M{LyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrUVpVLUUN3ME25Mlg2QTZ|IN88US=> NXizcpBnW0GQR1XS
THP-1 NI\nbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK5TWM2OD17Lkm2PVE5KM7:TR?= MYDTRW5ITVJ?
SHP-77 NHvSXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfUOm9KUUN3ME2xNE41ODdizszN NG\adplUSU6JRWK=
EW-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\x[2lEPTB;MUCuOlI5QSEQvF2= NEn0S2ZUSU6JRWK=
KY821 NHnEcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHYcWJKSzVyPUGwMlc3OyEQvF2= MnSyV2FPT0WU
NCI-SNU-1 NHvSOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjZTWM2OD1zMT6wNlE4KM7:TR?= NILiOodUSU6JRWK=
HCC2218 NX7STXRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES2enNKSzVyPUGxMlM6QDZizszN M3;1R3NCVkeHUh?=
IM-9 MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLoTWM2OD1zMT61NVA3KM7:TR?= M3TQc3NCVkeHUh?=
NCI-H889 MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFzLkWzNVMh|ryP MWXTRW5ITVJ?
HDLM-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLOeZlNUUN3ME2xNk41OTV7IN88US=> MWDTRW5ITVJ?
LB2518-MEL MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nqWmlEPTB;MUKuOlgyPSEQvF2= NHrHeVVUSU6JRWK=
NCI-H23 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjLc3NKSzVyPUGzMlI1OjVizszN NIrkeWNUSU6JRWK=
NB17 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF64U2dKSzVyPUGzMlQ2PzlizszN MVfTRW5ITVJ?
NCI-H322M MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jWbmlEPTB;MUSuOFA3QCEQvF2= NGWzWJRUSU6JRWK=
SUP-T1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f6T2lEPTB;MUSuOFE{KM7:TR?= Mm\UV2FPT0WU
ES3 NVj3e2VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LXRWlEPTB;MUWuNFcxOyEQvF2= NUTDb25QW0GQR1XS
ES5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF3LkC3PFch|ryP MmDpV2FPT0WU
NCI-H1650 M3frRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF3LkS5O|kh|ryP NUDIPJZYW0GQR1XS
NCI-H226 NEnnNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPJfpRGUUN3ME2xOU45PzZ6IN88US=> MoDhV2FPT0WU
COR-L88 NIi3XmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H3NWlEPTB;MU[uN|E1KM7:TR?= Moq0V2FPT0WU
SCC-15 NG\j[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz2ToJ5UUN3ME2xOk4{QDZ7IN88US=> Mo\WV2FPT0WU
GOTO MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrjOHNKSzVyPUG2MlQ4QTNizszN M3fnUHNCVkeHUh?=
SIMA NHnDOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF4LkS4NFIh|ryP M1\DR3NCVkeHUh?=
NCI-H1299 M4fMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\nTWM2OD1zNz6xOVkyKM7:TR?= NF\rU|dUSU6JRWK=
NCI-H1581 NFfqPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF5LkSyNVkh|ryP MXrTRW5ITVJ?
MHH-NB-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\mTWM2OD1zNz65Olg{KM7:TR?= NHTL[FVUSU6JRWK=
MFM-223 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\NTWM2OD1zOD6wOVM5KM7:TR?= NYf1PFdKW0GQR1XS
ES7 NYnMTYhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF6LkW0N|Eh|ryP MUfTRW5ITVJ?
JVM-3 M1;5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGewbpJKSzVyPUG4MlcyPyEQvF2= M1rYVXNCVkeHUh?=
RL MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPpbHRKSzVyPUKwMlM5QCEQvF2= MoHLV2FPT0WU
EC-GI-10 NXf1RmFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPYTotKSzVyPUKxMlIxPDFizszN NVTveXVRW0GQR1XS
LNCaP-Clone-FGC M13Bbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJzLk[3Olgh|ryP NIDuUHZUSU6JRWK=
IMR-5 MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXaWYJKSzVyPUKxMlg1QTRizszN NH\iRW1USU6JRWK=
KP-N-YS NFXwNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzUfmpOUUN3ME2yNU45PzVizszN Mlu5V2FPT0WU
Mo-T MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj6TWM2OD1{Mj6yNVg2KM7:TR?= M4G4e3NCVkeHUh?=
NCI-H128 NVL0U3BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrVTWM2OD1{Mz61PFU{KM7:TR?= MYTTRW5ITVJ?
RH-1 M{HESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnVc5pNUUN3ME2yN{44QDZ4IN88US=> MYnTRW5ITVJ?
NCI-H2171 M2rXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPsTWM2OD1{ND6yOFg2KM7:TR?= NFHMWmVUSU6JRWK=
RPMI-8866 M{TwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3tNopkUUN3ME2yOk44PDJizszN NYH0NGdMW0GQR1XS
SK-N-FI M3fkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJ5LkO4NVEh|ryP MnjvV2FPT0WU
LOXIMVI NY\xd5JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3i[oNKSzVyPUK3MlgxPTFizszN NHTtXGxUSU6JRWK=
P31-FUJ M2jlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljtTWM2OD1|MT61N|c1KM7:TR?= NGDVZXVUSU6JRWK=
KMS-12-PE NF;1T2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj1cVZlUUN3ME20PU42OzB{IN88US=> NV;aVo96W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03531281 Not yet recruiting Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic Cell Transplantation Recipient City of Hope Medical Center|National Cancer Institute (NCI) December 30 2018 Phase 1
NCT03298958 Not yet recruiting Bladder Cancer The University of Texas Health Science Center at San Antonio December 1 2018 Phase 3
NCT03433183 Not yet recruiting Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1 Sarcoma Alliance for Research through Collaboration|United States Department of Defense|AstraZeneca December 2018 Phase 2
NCT03721614 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. December 1 2018 Not Applicable
NCT03203525 Not yet recruiting Liver Cancer M.D. Anderson Cancer Center|NovoCure Ltd. December 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID